Introduction
EIF5A2 (eukaryotic translation initiation factor 5A2) is a protein-coding gene that encodes one of the two isoforms of the eukaryotic initiation factor 5A (eIF5A) family in humans. While the canonical eIF5A1 is ubiquitously expressed and essential for cell viability, EIF5A2 is expressed at lower levels in most tissues but is strongly upregulated in several cancers and during certain developmental stages. The EIF5A2 protein is distinguished from eIF5A1 by only a few amino acid substitutions, yet it has distinct regulatory properties and functional roles that are increasingly recognized in cellular growth, proliferation, and disease pathology.
Gene and Protein
Gene Characteristics
The EIF5A2 gene resides on human chromosome 8p22. It spans approximately 16 kilobases and contains nine exons. The promoter region of EIF5A2 is enriched in GC content and contains binding sites for transcription factors such as MYC and SP1, which contribute to its inducible expression under oncogenic stimuli. Alternative splicing generates at least two transcript variants, one of which produces a protein isoform with an extended C‑terminal tail that may modulate subcellular localization.
Protein Structure and Post‑Translational Modifications
EIF5A2 is a highly conserved protein of 137 amino acids. Its primary sequence shares ~94 % identity with EIF5A1, differing mainly at positions 5, 21, 53, and 94. The protein folds into a compact beta‑sheet scaffold with a central alpha‑helix, characteristic of the eIF5A family. A key post‑translational modification is the conversion of a specific lysine residue to hypusine, catalyzed by the enzymes deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH). Hypusination is essential for the catalytic activity of both eIF5A1 and EIF5A2, enabling interaction with ribosomes and tRNA during translation.
Subcellular Localization
Under steady‑state conditions, EIF5A2 localizes predominantly to the cytoplasm, where it associates with polysomes and ribosomal subunits. Immunofluorescence studies have revealed transient nuclear import of EIF5A2 during mitosis, suggesting a role in cell cycle progression. The nuclear export signal (NES) in its C‑terminus is essential for maintaining cytoplasmic distribution, and mutations disrupting this signal result in nuclear retention and impaired translation of specific mRNAs.
Biological Function
Role in Translation Initiation
Although eIF5A1 was first characterized as a translation initiation factor, the consensus view now places eIF5A proteins primarily at the elongation stage, facilitating the synthesis of peptides that contain ribosomal stalling motifs such as consecutive prolines or poly‑arginine stretches. EIF5A2 exhibits similar activity but displays a higher affinity for specific mRNAs associated with ribosomal frameshifting and stop‑codon read‑through, thereby influencing the proteome composition in proliferating cells.
Interaction with Other Ribosomal Factors
Co‑immunoprecipitation experiments have shown that EIF5A2 interacts with ribosomal protein L7 and the elongation factor EF‑1α. These interactions are enhanced during stress conditions such as hypoxia or nutrient deprivation, suggesting that EIF5A2 contributes to the adaptive translational reprogramming that supports cell survival.
Influence on Signal Transduction Pathways
EIF5A2 indirectly modulates several signaling cascades. Overexpression of EIF5A2 up‑regulates the PI3K/AKT pathway by enhancing translation of PI3K regulatory subunits, thereby promoting cell proliferation. Conversely, knockdown of EIF5A2 leads to decreased phosphorylation of AKT and downstream effectors, confirming its regulatory role in growth‑factor signaling.
Regulation and Expression
Transcriptional Control
The EIF5A2 promoter contains binding motifs for oncogenic transcription factors, including MYC, NF‑κB, and HIF‑1α. In hypoxic tumor microenvironments, HIF‑1α stabilizes and binds the promoter, inducing EIF5A2 transcription. This mechanism accounts for the frequent up‑regulation of EIF5A2 in solid tumors such as breast, colorectal, and lung cancers.
Post‑Transcriptional Mechanisms
MicroRNAs (miRNAs) that target EIF5A2 mRNA have been identified, with miR‑15b and miR‑181c reported to bind the 3′UTR and suppress translation. During embryonic development, the dynamic expression of these miRNAs modulates EIF5A2 levels, coordinating cellular proliferation with differentiation processes.
Epigenetic Modifications
DNA methylation of CpG islands within the EIF5A2 promoter region correlates inversely with gene expression. Hypomethylation is frequently observed in malignant tissues, leading to derepression of EIF5A2. Chromatin immunoprecipitation assays have shown enrichment of H3K4me3 marks at the promoter during active transcription, whereas H3K27me3 is associated with silencing in differentiated somatic cells.
Developmental Roles
Embryogenesis
During early embryogenesis, EIF5A2 expression peaks in the inner cell mass of blastocysts and in the neuroepithelium of the developing brain. Loss‑of‑function studies in zebrafish embryos using morpholino antisense oligonucleotides demonstrate defects in neural tube closure and cardiogenesis, underscoring a requirement for EIF5A2 in embryonic patterning.
Stem Cell Maintenance
Human embryonic stem cells (hESCs) exhibit high levels of EIF5A2, which decline upon differentiation. Overexpression of EIF5A2 in hESCs prolongs the pluripotent state by maintaining expression of core pluripotency transcription factors, whereas knockdown accelerates spontaneous differentiation into ectodermal lineages.
Organogenesis
In murine models, conditional deletion of EIF5A2 in the developing pancreas results in impaired β‑cell proliferation and reduced insulin production. Similar phenotypes are observed in liver-specific knockouts, where hepatocyte proliferation is diminished during postnatal growth, leading to organ hypoplasia.
Involvement in Human Diseases
Cancer
EIF5A2 over‑expression is one of the most consistent findings in human malignancies. It has been reported in breast, colorectal, gastric, ovarian, prostate, pancreatic, and hepatocellular carcinomas, among others. High EIF5A2 expression correlates with increased tumor grade, lymph node metastasis, and reduced overall survival across multiple cancer types.
Mechanisms of Oncogenicity
EIF5A2 promotes oncogenesis through several mechanisms: (1) enhanced translation of oncogenic mRNAs such as c‑MET, KRAS, and cyclin D1; (2) suppression of tumor suppressor pathways via down‑regulation of PTEN and p53; (3) facilitation of epithelial‑to‑mesenchymal transition (EMT) by up‑regulating transcription factors like Snail and Twist; and (4) modulation of the tumor microenvironment through increased secretion of pro‑angiogenic factors such as VEGF.
Other Pathological Conditions
Beyond cancer, elevated EIF5A2 levels have been implicated in neurodegenerative disorders. In a mouse model of amyotrophic lateral sclerosis (ALS), EIF5A2 over‑expression accelerated motor neuron loss, potentially through dysregulation of translation fidelity. In cardiovascular disease, EIF5A2 deficiency predisposes mice to myocardial infarction by impairing cardiac myocyte proliferation during the repair phase.
Role in Cancer
Breast Cancer
In invasive ductal carcinoma, EIF5A2 expression is 4‑fold higher in metastatic lesions than in primary tumors. Functional assays reveal that silencing EIF5A2 reduces cell migration by 60 % and invasion by 70 %. Transcriptomic profiling shows that EIF5A2 knockdown leads to down‑regulation of MMP9 and VEGF, correlating with decreased angiogenesis in xenograft models.
Colorectal Cancer
Patients with stage III colorectal cancer exhibit elevated EIF5A2 levels in circulating tumor cells (CTCs). In vitro, over‑expression of EIF5A2 confers resistance to 5‑fluorouracil, possibly through up‑regulation of thymidylate synthase. Conversely, CRISPR‑Cas9 mediated knockout of EIF5A2 restores drug sensitivity.
Gastric and Pancreatic Cancer
In gastric carcinoma, EIF5A2 cooperates with HER2 amplification to enhance cell proliferation. In pancreatic ductal adenocarcinoma (PDAC), EIF5A2 up‑regulates the transcription factor SOX2, promoting stem‑cell‑like properties. In both cases, pharmacological inhibition of the hypusination pathway using GC7 reduces tumor growth in mouse models.
Therapeutic Targeting
Several strategies have emerged to target EIF5A2: (1) small‑molecule inhibitors of DHS (e.g., GC7, ciclopirox) block hypusination, thereby impairing EIF5A2 function; (2) antisense oligonucleotides or siRNAs directed against EIF5A2 mRNA suppress its expression; and (3) immunotherapy approaches employing bispecific T‑cell engagers to target cells over‑expressing EIF5A2. Preclinical studies indicate that combination therapies with standard chemotherapeutics potentiate tumor regression.
Other Pathological Conditions
Neurodegenerative Diseases
In models of Parkinson’s disease, EIF5A2 over‑expression exacerbates dopaminergic neuron loss, possibly through increased production of α‑synuclein via translational dysregulation. In Alzheimer’s disease, elevated EIF5A2 correlates with amyloid‑β plaque burden, suggesting a contributory role in plaque formation.
Infectious Diseases
Certain viral pathogens exploit EIF5A2 to enhance their replication. For example, human papillomavirus (HPV) E6 protein stabilizes EIF5A2, which in turn promotes the synthesis of viral proteins that interfere with host immune responses. Inhibition of EIF5A2 reduces viral load in infected cell cultures, highlighting its potential as an antiviral target.
Animal Models
Genetic Knockout Mice
Global deletion of EIF5A2 in mice is embryonically lethal, indicating an essential developmental role. Conditional knockout models (e.g., using Cre‑loxP technology) reveal tissue‑specific phenotypes: liver‑specific deletion impairs hepatocyte proliferation; brain‑specific deletion leads to neurodevelopmental deficits and impaired learning.
Transgenic Overexpression Models
Transgenic mice over‑expressing EIF5A2 under the control of the human cytokeratin 18 promoter develop spontaneous mammary tumors with high penetrance. Tumors exhibit increased angiogenesis and metastatic potential, mirroring human breast cancer features.
Zebrafish Models
Morpholino knockdown of eif5a2 in zebrafish embryos causes craniofacial cartilage defects and impaired cardiac looping, underscoring its role in vertebrate morphogenesis. Rescue experiments with human EIF5A2 mRNA restore normal development, confirming functional conservation.
Therapeutic Potential
Targeting Hypusination
Given that hypusination is indispensable for EIF5A2 activity, inhibitors of DHS and DOHH present a viable therapeutic strategy. GC7, a selective DHS inhibitor, has shown efficacy in reducing tumor growth in multiple xenograft models. More potent DHS inhibitors, such as N,N′‑bis‑(2‑deoxyhypusine)‑methane, are under preclinical investigation.
RNA‑Based Interventions
siRNA and antisense oligonucleotides (ASOs) directed against EIF5A2 mRNA have demonstrated tumor growth inhibition in vivo. Delivery challenges are being addressed using lipid nanoparticles or conjugation to cell‑penetrating peptides.
Immunotherapy
EIF5A2 is immunogenic in certain contexts; peptide vaccines targeting EIF5A2 epitopes have induced cytotoxic T‑cell responses in murine models of melanoma. Bispecific antibodies that link CD3 on T cells to EIF5A2‑expressing tumor cells show promising antitumor activity.
Current Research
Structural Biology
High‑resolution crystal structures of human EIF5A2 in complex with ribosomal subunits are being resolved. These structures aim to delineate the precise interface between EIF5A2 and the ribosome, potentially revealing druggable pockets for small‑molecule inhibition.
Systems Biology
Integrative omics analyses (transcriptomics, proteomics, ribosome profiling) are identifying EIF5A2‑dependent translational networks. Data indicate that EIF5A2 preferentially enhances translation of mRNAs encoding proteins with high proline content, reinforcing its role in modulating proteome composition.
Clinical Trials
Early phase clinical trials evaluating DHS inhibitors in patients with advanced solid tumors are ongoing. Biomarker studies assess EIF5A2 expression levels and correlate them with therapeutic response, offering insight into patient stratification.
Future Directions
Future research will focus on elucidating the full spectrum of EIF5A2’s biological functions beyond translation, including its involvement in RNA metabolism, protein quality control, and intercellular signaling. Development of highly selective, orally bioavailable DHS inhibitors and targeted delivery systems for RNA therapeutics will be pivotal for translating EIF5A2 inhibition into clinical practice. Additionally, comprehensive profiling of EIF5A2’s post‑translational modifications may reveal novel regulatory mechanisms and therapeutic opportunities.
No comments yet. Be the first to comment!